BioVersys Awarded Non-Dilutive Funding From CF AMR Syndicate Collaborative Discovery Programme BASEL, Switzerland, June 04, 2024 (GLOBE NEWSWIRE) -- CF AMR Syndicate awarded BioVersys up to £ 500,000 to support project addressing resistant non-tubercular mycobacteria (NTM) lung infections...

BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million Strategic collaboration with GSK expanded to accelerate clinical development of alpibectir for the treatment of tuberculosisGSK to participate in Series C Extension with equity investmentSeries C...